Strategic Initiative

Slingshot members are tracking this corporate initiative:

Bristol-Myers Squibb (BMY) Signs Exclusive Worldwide License Agreement with Nitto Denko (NDEKY) for siRNA Therapy in Advanced Non-Alcoholic Steatohepatitis (NASH) and Cirrhosis

Source Link:: http://investor.bms.com/investors/news-and-events/press-releases/press-release-details/2016/Bristol-Myers-Squibb-Signs-Exclusive-Worldwide-License-Agreement-with-Nitto-Denko-for-Targeted-siRNA-Therapy-in-Advanced-Non-alcoholic-Steatohepatitis-NASH-and-Cirrhosis-Due-to-NASH/default.aspx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BMY

100%

NDEKY

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Nov 10, 2016

Projected Implementation:

Q4, 2016

Relevance Tracked Until:

Q4, 2018

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Global Commercialization Rights, Development Rights, Liver Fibrosis Candidates, Exclusive Worldwide License Agreement, Sirna Therapy, Advanced Non-alcoholic Steatohepatitis, Nash, Cirrhosis